Newly launched include generics of Spiriva HandiHaler, Forteo, Livalo and Farxiga.
Lupin has launched its generic version of Spiriva HandiHaler. Lupin’s tiotropium bromide inhalation powder capsule is approved to treat patients with chronic obstructive pulmonary disease (COPD).
Additionally, the FDA has approved several generic products developed by Lupin. Pitavastatin tablets, 1 mg, 2 mg, and 4 mg and a generic equivalent of Livalo, was approved to treat adults with primary hyperlipidemia, and adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia.
Lupin has also received tentative approval from the FDA for dapagliflozin tablets, 5 mg, and 10 mg to market a generic equivalent of Farxiga, which is used to treat patients with diabetes. Both products will be manufactured at Lupin’s Pithampur facility in India.
Lupin also received FDA approval of ganirelix acetate injection, 250 mcg/0.5 mL single-dose prefilled syringe, which is used for infertility treatment. It will be manufactured at Lupin’s Nagpur facility in India.
In other generic news:
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More